CA2811662A1 - Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c - Google Patents
Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c Download PDFInfo
- Publication number
- CA2811662A1 CA2811662A1 CA2811662A CA2811662A CA2811662A1 CA 2811662 A1 CA2811662 A1 CA 2811662A1 CA 2811662 A CA2811662 A CA 2811662A CA 2811662 A CA2811662 A CA 2811662A CA 2811662 A1 CA2811662 A1 CA 2811662A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- membered
- occurrence
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2010/077493 | 2010-09-29 | ||
PCT/CN2010/077493 WO2012040923A1 (fr) | 2010-09-29 | 2010-09-29 | Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales |
US201061426724P | 2010-12-23 | 2010-12-23 | |
US61/426,724 | 2010-12-23 | ||
PCT/CN2011/001638 WO2012041014A1 (fr) | 2010-09-29 | 2011-09-28 | Dérivés d'indoles tétracycliques pour le traitement d'une infection par le virus de l'hépatite c |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2811662A1 true CA2811662A1 (fr) | 2012-04-05 |
Family
ID=45891857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2811662A Abandoned CA2811662A1 (fr) | 2010-09-29 | 2011-09-28 | Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP2621931A4 (fr) |
JP (1) | JP2013538831A (fr) |
KR (1) | KR20140001879A (fr) |
AU (1) | AU2011307953B2 (fr) |
BR (1) | BR112013007696A2 (fr) |
CA (1) | CA2811662A1 (fr) |
MX (1) | MX2013003631A (fr) |
WO (1) | WO2012041014A1 (fr) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
JP5582662B2 (ja) | 2009-05-13 | 2014-09-03 | ギリアード サイエンシーズ, インコーポレイテッド | 抗ウイルス化合物 |
CN102333772B (zh) | 2009-06-11 | 2013-12-11 | 雅培制药有限公司 | 抗病毒化合物 |
US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
EP2550267A1 (fr) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analogues pour traiter ou prévenir les infections à flavivirus |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
EP2963034A1 (fr) | 2010-08-26 | 2016-01-06 | RFS Pharma, LLC. | Inhibiteurs puissants et sélectifs du virus de l'hépatite c |
US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
AU2012283609B2 (en) | 2011-07-09 | 2016-09-29 | Sunshine Lake Pharma Co., Ltd. | Spiro compounds as hepatitis C virus inhibitors |
WO2013030750A1 (fr) | 2011-09-01 | 2013-03-07 | Lupin Limited | Composés antiviraux |
DE202012013074U1 (de) | 2011-09-16 | 2014-10-29 | Gilead Pharmasset Lcc | Zusammensetzungen zur Behandlung von HCV |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG11201404475TA (en) | 2012-02-10 | 2014-08-28 | Lupin Ltd | Antiviral compounds with a dibenzooxaheterocycle moiety |
TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
TWI585082B (zh) | 2012-11-29 | 2017-06-01 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的螺環化合物、藥物組合物及它們的用途 |
US9802949B2 (en) | 2012-11-29 | 2017-10-31 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof |
WO2014110688A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques à substitution thiophène et leurs procédés d'utilisation pour le traitement des maladies virales |
WO2014110687A1 (fr) * | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par thiazolyle et leurs procédés d'utilisation pour le traitement de maladies virales |
SG10201706949VA (en) | 2013-01-31 | 2017-09-28 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014121417A1 (fr) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c |
WO2014121418A1 (fr) * | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c |
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CN105837561B (zh) * | 2013-06-06 | 2019-06-28 | 上海爱博医药科技有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
CN105530933B (zh) | 2013-07-17 | 2018-12-11 | 百时美施贵宝公司 | 用于治疗hcv的包含联苯衍生物的组合产品 |
EP4005560A1 (fr) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Formulation de combinaison de deux composés antiviraux |
EP3063145A4 (fr) * | 2013-10-30 | 2017-08-23 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques |
WO2015089810A1 (fr) * | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Composés tétracycliques hétérocycliques condensés et leurs procédés d'utilisation pour le traitement de maladies virales |
WO2015103490A1 (fr) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Formes galéniques antivirales solides |
WO2015110048A1 (fr) | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Composés cycliques pontés comme inhibiteurs du virus de l'hépatite c, compositions pharmaceutiques et utilisations correspondantes |
US20170166586A1 (en) | 2014-07-11 | 2017-06-15 | Hongming Li | Process for making tetracyclic heterocycle compounds |
WO2016196932A1 (fr) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Procédé de préparation de composés hétérocycliques tétracycliques substitués |
WO2017023631A1 (fr) | 2015-08-06 | 2017-02-09 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
CN108290904B (zh) * | 2015-12-10 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 氘修饰的elbasvir衍生物、含有该化合物的药物组合物及其用途 |
WO2017181947A1 (fr) * | 2016-04-20 | 2017-10-26 | 深圳市塔吉瑞生物医药有限公司 | Carbamate substitué de diamine, composition pharmaceutique et application correspondante |
WO2018032467A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par chromane et leurs utilisations dans le traitement de maladies virales |
WO2018032468A1 (fr) * | 2016-08-18 | 2018-02-22 | Merck Sharp & Dohme Corp. | Composés tétracycliques substitués par hétérocycles et leurs procédés d'utilisation pour le traitement de maladies virales |
RU2659388C1 (ru) | 2017-02-28 | 2018-07-02 | Васильевич Иващенко Александр | Нуклеотиды, включающие N-[(S)-1-циклобутоксикарбонил]фосфорамидатный фрагмент, их аналоги и их применение |
RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
US7745636B2 (en) * | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
DK2373172T3 (da) * | 2008-12-03 | 2013-10-21 | Presidio Pharmaceuticals Inc | Hcv-ns5a-hæmmere |
US9120779B2 (en) * | 2008-12-03 | 2015-09-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
RS54713B1 (en) * | 2009-03-27 | 2016-08-31 | Merck Sharp & Dohme Corp. | HEPATITIS VIRUS REPLICATION INHIBITORS C |
-
2011
- 2011-09-28 JP JP2013530529A patent/JP2013538831A/ja not_active Withdrawn
- 2011-09-28 MX MX2013003631A patent/MX2013003631A/es not_active Application Discontinuation
- 2011-09-28 KR KR1020137010717A patent/KR20140001879A/ko not_active Application Discontinuation
- 2011-09-28 AU AU2011307953A patent/AU2011307953B2/en not_active Expired - Fee Related
- 2011-09-28 WO PCT/CN2011/001638 patent/WO2012041014A1/fr active Application Filing
- 2011-09-28 EP EP11827912.4A patent/EP2621931A4/fr not_active Withdrawn
- 2011-09-28 CA CA2811662A patent/CA2811662A1/fr not_active Abandoned
- 2011-09-28 BR BR112013007696A patent/BR112013007696A2/pt not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2012041014A1 (fr) | 2012-04-05 |
JP2013538831A (ja) | 2013-10-17 |
KR20140001879A (ko) | 2014-01-07 |
EP2621931A1 (fr) | 2013-08-07 |
AU2011307953A1 (en) | 2013-04-04 |
EP2621931A4 (fr) | 2014-03-19 |
AU2011307953B2 (en) | 2014-07-31 |
MX2013003631A (es) | 2013-10-01 |
BR112013007696A2 (pt) | 2019-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2811662A1 (fr) | Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c | |
EP2685984B1 (fr) | Dérivés tétracycliques de xanthène et leurs méthodes d'utilisation en vue du traitement de maladies virales | |
EP2621279B1 (fr) | Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales | |
CA2898049C (fr) | Composes tetracycliques substitues par un heterocycle et procedes pour les utiliser pour le traitement de maladies virales | |
KR20130008040A (ko) | 융합된 트리시클릭 실릴 화합물 및 바이러스성 질환의 치료를 위한 그의 사용 방법 | |
WO2012040923A1 (fr) | Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales | |
WO2011087740A1 (fr) | Composés tricycliques fusionnés et leurs méthodes d'utilisation pour le traitement de maladies virales | |
CA2805440A1 (fr) | Composes de biphenylene substitue et procedes d'utilisation desdits composes pour le traitement de maladies virales | |
EP2621932A1 (fr) | Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c | |
WO2012040924A1 (fr) | Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales | |
EP2435421A1 (fr) | Composés antiviraux constitués de trois fractions d'aryle alignées pour traiter des maladies telles que l'hépatite c | |
WO2012003642A1 (fr) | Composés tricycliques condensés et leur utilisation pour le traitement de maladies virales | |
WO2013033900A1 (fr) | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales | |
CA2898051A1 (fr) | Composes tetracycliques a substitution thiophene et leurs mehodes d'utilisation pour le traitement de maladies virales | |
US20150057246A1 (en) | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases | |
WO2013039876A1 (fr) | Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales | |
WO2017112531A1 (fr) | Composés hétérocycliques contenant un silane et méthodes d'utilisation desdits composés pour traiter les maladies virales |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20150929 |